← Back to Search

Antisense Oligonucleotide

A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection

Phase 2
Waitlist Available
Research Sponsored by Assembly Biosciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and 56.
Awards & highlights
No Placebo-Only Group

Summary

This trial tests two new drugs, vebicorvir and AB-729, along with a standard treatment for chronic hepatitis B. It aims to see if this combination is safer and more effective. The drugs work by stopping the virus from multiplying and reducing viral proteins.

Eligible Conditions
  • Chronic Hepatitis B

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and 56.
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and 56. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change From Baseline in Mean log10 HBV RNA On-Treatment
Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) On-Treatment

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: VBR + SOC NrtIExperimental Treatment2 Interventions
Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up. This treatment was used as a reference regimen.
Group II: VBR + AB-729 + SOC NrtIExperimental Treatment3 Interventions
Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up.
Group III: AB-729 + SOC NrtIExperimental Treatment2 Interventions
Participants with cHBV received AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up. This treatment was used as a reference regimen.

Find a Location

Who is running the clinical trial?

Assembly BiosciencesLead Sponsor
20 Previous Clinical Trials
1,279 Total Patients Enrolled
Arbutus Biopharma CorporationIndustry Sponsor
12 Previous Clinical Trials
592 Total Patients Enrolled
~14 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top